November 10-15

The official news source of

ACR Convergence 2023

San Diego, CA

  • The right tech tools improve rheumatology practices

    The right tech tools improve rheumatology practices

    “Every ten minutes of computer time we can automate is another ten minutes we can spend with patients,” said Paul Sufka, MD.

  • Learn how to answer SpA patients’ tough questions

    Learn how to answer SpA patients’ tough questions

    Robert Inman, MD, Professor of Medicine and Immunology at University Health Network and University of Toronto, will offer the latest data and current thinking in response to common patient questions during Current State of the Art in Spondyloarthritides (SpA): Tough Questions Your SpA Patients Might Ask You.

  • Interest in wearable biosensors outpaces research

    Interest in wearable biosensors outpaces research

    Brennan Spiegel, MD, MSHS,will discuss some of the unexpected insights coming from one of the first formal rheumatology studies incorporating wearable biosensors during a clinical symposium on Monday.

  • Rheumatology close to seeing influx of biosimilars

    Rheumatology close to seeing influx of biosimilars

    Joseph E. Huffstutter, MD, will offer a preview of the ever-changing regulatory journey for biosimilars during a clinical symposium. Two dozen biosimilars have been approved worldwide, Dr. Huffstutter said.

  • Emotional support for rheumatology patients lacking

    Emotional support for rheumatology patients lacking

    “Providing psychological support is part of our task under guidelines, but there is evidence that this is not happening,” said Sarah Hewlett, PhD, MA, RN. “There is quite a lot of evidence that we are not.”

  • Experts reconsider value of serial ANCA testing for many patients

    Experts reconsider value of serial ANCA testing for many patients

    Antibody testing results don’t offer simple black-or-white answers. A positive antinuclear antibody (ANA) test does not lead to an automatic diagnosis of autoimmune rheumatic disease, and multiple anti-neutrophil cytoplasmic antibody (ANCA) testing is not always clinically helpful or even appropriate.

  • Incorporating patient into treatment discussion is important for arthritis self-management

    Incorporating patient into treatment discussion is important for arthritis self-management

    There was a time when what passed for arthritis patient education was the clinician simply telling the patient about the condition.

  • New targeted biologics emerge as the next  generation of rheumatologic therapies

    New targeted biologics emerge as the next generation of rheumatologic therapies

    Biologics are a relatively new class of drugs that have been used and studied for almost 20 years, and many new targeted biologics known as bDMARDs have emerged with the promise of not only providing better treatment for rheumatic diseases, but also the potential of having fewer side effects than conventional DMARDs.

  • Non-pharmacological approach to fibromyalgia proves helpful

    Non-pharmacological approach to fibromyalgia proves helpful

    The lack of objective measurement or biomarker for assessment of fibromyalgia patients makes treating the condition a challenge, said Mary-Ann Fitzcharles, MD, Rheumatologist and Researcher at the McGill University Health Centre in Canada and an Associate Professor of Medicine at McGill University.

  • Q&A: Foundation builds interest, advances careers

    Q&A: Foundation builds interest, advances careers

    Lindsey Criswell, MD, MPH, DSc, has received several awards from the Rheumatology Research Foundation, including the Pilot Grant, which encourages investigators to expand promising research into rheumatoid arthritis and related autoinflammatory diseases by providing support to established researchers.